No, not on a standard test. The 5 panel, 10 panel, and 12 panel immunoassay cups and dip cards used in most workplace and clinical drug testing programs do not detect kratom or its active alkaloid, mitragynine. These panels are built around antibodies that target specific drug classes, such as THC, cocaine metabolite, opiates, amphetamines, and PCP, and mitragynine's chemical structure does not trigger a positive on any of them. Catching kratom use requires a dedicated kratom or mitragynine screening device, or laboratory confirmation.
For HR and safety managers, collectors, MROs, clinics, and treatment programs, that gap matters. Kratom is legal to sell and possess under federal law, widely available online, and increasingly used as a self-treatment for pain or opioid withdrawal. This guide covers why standard panels miss it, what the legal picture looks like, and how buyers add kratom detection to an existing testing program.
Why Standard Multi-Panel Tests Do Not Catch Kratom
Rapid urine drug test cups and dip cards work through immunoassay technology. Each test strip contains antibodies engineered to bind to a specific drug or drug class. The opiate strip on a standard cup, for example, is built to react with morphine, codeine, and closely related compounds such as hydrocodone, oxycodone, dihydrocodeine, and 6 acetylmorphine (a heroin metabolite). A laboratory reference document from Oregon Health and Science University's Department of Pathology, which catalogs cross reactivity across immunoassay drug classes, lists dozens of compounds that do and do not trigger a positive on standard panels. Kratom and mitragynine do not appear anywhere on that list, because mitragynine is a distinct indole alkaloid rather than a morphinan opioid.
The DEA's drug fact sheet on kratom describes mitragynine as kratom's most abundant alkaloid, making up roughly two thirds of the plant's total alkaloid content, with 7 hydroxymitragynine present in much smaller amounts. Both compounds act on opioid receptors similarly to morphine in preclinical studies, but their chemical backbone differs enough from classic opiates that standard antibodies do not recognize them. A person who uses kratom heavily can pass a standard 5, 10, or 12 panel screen every time, even though the substance is active in their system.
What Kratom Is, and Why Testing Programs Are Paying Attention
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, related to the coffee plant. According to the DEA fact sheet, kratom has no legitimate medical use in the United States, produces stimulant effects at low doses and sedative, opioid like effects at high doses, and carries a documented risk of addiction, withdrawal, and psychosis with chronic use. The same fact sheet cites America's Poison Centers data showing kratom was involved in nearly 1,500 case mentions in a single year, including cases requiring healthcare facility treatment and several deaths, and cites FDA adverse event data linking kratom to over 700 deaths reported between 2008 and 2025.
Kratom is commonly used as a substitute for prescription opioids, a self-treatment for opioid use disorder, or a way to manage withdrawal symptoms. That makes it relevant to two groups in particular. Pain clinics monitoring patients on controlled substance regimens want to know if a patient is combining prescribed medication with an unregulated, opioid receptor active substance. Treatment centers and rehab programs monitoring recovery want to know if a client is substituting kratom for the substance they are supposedly avoiding. Neither group learns anything from a standard panel, because kratom simply is not on it.
Kratom's Legal Status Is a State by State Patchwork
Kratom is not a controlled substance or listed chemical under the federal Controlled Substances Act. The DEA has listed it as a Drug and Chemical of Concern, a category that lets the agency monitor the substance without formally scheduling it. DEA moved to place kratom's alkaloids into Schedule I on an emergency basis in 2016, then withdrew that notice after public and congressional pushback, and has not attempted federal scheduling since. The FDA has approved no drug products containing kratom, mitragynine, or 7 hydroxymitragynine, treats kratom as an unapproved new dietary ingredient that cannot legally be marketed as a supplement or food additive, and has issued repeated import alerts and product seizures.
States have filled the gap with a genuine patchwork. A Congressional Research Service legal review found that roughly two dozen states have taken some regulatory action on kratom, split into two camps: a handful of states ban mitragynine and its related alkaloids outright under state law analogues of the Controlled Substances Act, while a larger group regulates sale, age limits, labeling, or contaminant testing without banning the plant itself. The specific list changes as legislatures act, so buyers with multi-state operations should not rely on any static list, including this one. Check your state's current statute, or the DEA and FDA pages above, before writing a kratom policy that assumes a specific state's rule.
How to Actually Detect Kratom Use
Because kratom is not part of any standard panel, detection has to be built in deliberately, in one of two ways.
Specialty kratom or mitragynine immunoassay
Dedicated single analyte screening devices exist specifically to flag mitragynine, separate from the standard drug classes. These work like any other immunoassay screen: fast and presumptive, requiring confirmation on any non-negative result before anyone treats it as proof of use.
Laboratory confirmation
Because kratom's alkaloids are structurally unusual, confirmation testing by gas or liquid chromatography paired with mass spectrometry (GC-MS or LC-MS/MS) is the only way to identify and quantify mitragynine with legal or clinical certainty, the same standard used to confirm any non-negative screen before it affects a patient's treatment plan or an employee's job status.
| Test type | Detects kratom/mitragynine | Method | Best use |
|---|---|---|---|
| Standard 5, 10, or 12 panel cup or dip card | No | Immunoassay, targets THC, cocaine, opiates, amphetamines, PCP and similar classes | General pre-employment, random, and DOT-style programs where kratom is not a stated concern |
| Specialty kratom or mitragynine immunoassay | Screens presumptively, yes | Immunoassay, single analyte or added to an expanded panel | Pain clinics and treatment programs that specifically want kratom flagged |
| Laboratory confirmation (GC-MS or LC-MS/MS) | Confirms and quantifies, yes | Chromatography paired with mass spectrometry | Confirming any non-negative kratom screen before it is treated as a positive result |
Why Treatment Centers and Pain Clinics Add Kratom Panels
Standard multi-panel drug testing cups cover the substances most programs care about across a broad population: marijuana, cocaine, opiates, amphetamines, PCP, and increasingly fentanyl. Kratom sits outside that core group because it is not federally controlled and its use pattern is narrower. But for two buyer types, it is often worth the added cost of a specialty panel.
Pain management programs monitoring patients on chronic opioid therapy want visibility into anything that changes a patient's opioid receptor activity, including an unregulated botanical product a patient may not think to disclose. Addiction treatment and rehab programs monitoring clients in recovery from opioid use disorder have a direct clinical interest in knowing whether a client has substituted kratom for the substance treatment is meant to address, since kratom is explicitly used for that purpose. ASC's pain management and pain clinic drug testing collection and addiction recovery drug and alcohol testing collection are built around exactly this kind of expanded, program-specific monitoring.
Building a Kratom Testing Protocol Without Guessing
- Decide who needs it. General pre-employment programs may not need kratom testing. Pain clinics and treatment programs usually do.
- Choose a screening format. Start from a broad, reliable base panel using ASC's drug testing cups collection, then add kratom or mitragynine screening where the protocol calls for it.
- Never treat a screen as final. Any non-negative kratom result is presumptive only and needs laboratory confirmation before anyone acts on it. ASC's laboratory and reference lab drug testing supplies collection supports that workflow, and the guide to what lab confirmation does after a non-negative screen explains the process.
- Document the legal basis. Cite the current state statute directly rather than a secondhand list, since state rules change.
- Train collectors and reviewers. A negative standard panel says nothing about kratom use one way or the other.
ASC's guide to what treatment centers should look for in a drug test supplier covers panel selection, CLIA waived status, and inventory reliability for programs building out an expanded testing protocol.
Frequently Asked Questions
Does a standard 12 panel drug test detect kratom?
No. Standard 5, 10, and 12 panel immunoassay cups and dip cards target THC, cocaine metabolite, opiates, amphetamines, PCP, and similar drug classes. Mitragynine, kratom's main active alkaloid, is not one of the analytes those panels are built to detect.
Is kratom the same as an opiate on a drug test?
No. Standard opiate immunoassay strips are built to react with morphine, codeine, and closely related compounds like hydrocodone and oxycodone. Mitragynine has a different chemical structure and does not reliably trigger a positive opiate result, even though it acts on some of the same opioid receptors in the body.
Is kratom legal?
Kratom is not a controlled substance under the federal Controlled Substances Act, and the DEA lists it as a Drug and Chemical of Concern rather than a scheduled drug. State law varies: some states ban kratom's active alkaloids outright, others regulate sale, age limits, or labeling without banning it, and the details change as state legislatures act. Confirm the current rule for any specific state before relying on it.
How do you test specifically for kratom?
Detecting kratom requires a dedicated kratom or mitragynine screening device, separate from a standard multi-panel cup, followed by laboratory confirmation using GC-MS or LC-MS/MS on any non-negative result.
Why would a pain clinic or treatment center test for kratom specifically?
Kratom is commonly used as a self-treatment for pain, opioid withdrawal, or opioid use disorder. Pain clinics want visibility into anything affecting a patient's opioid receptor activity, and treatment programs monitoring recovery have a direct interest in knowing whether a client has substituted kratom for the substance their treatment plan addresses.
Does a positive kratom screen prove someone used kratom?
No. A non-negative screening result on any immunoassay device, including a kratom specific one, is presumptive only. It requires laboratory confirmation before it should be treated as a confirmed positive result.
Compliance and Accuracy Note
Drug test cups, dip cards, and other screening devices provide presumptive screening results, not a diagnosis. Any non-negative screening result should be treated as preliminary and confirmed through laboratory testing before any employment, clinical, or legal action is taken. This article is informational only and is not legal or medical advice; verify current federal and state law, and consult qualified counsel, before implementing a testing policy.
